🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Obesity Prevention in School-aged Children
NCT07203300Childhood Obesity Prevention
Peking University
Not applicable
1,400
Beijing
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Active, closed
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07480863Marginal Zone Lymphoma(MZL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2025-10-01
Recruiting
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
NCT07301892Rheumatoid Arthritis (RA, Osteoporosis, Osteoarthritis, Interstitial Lung Disease
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
100
Beijing
2025-10-01
Not yet open
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
NCT07173933Wilson Disease
GeneCradle Inc
Phase 1/2
15
Beijing
2025-10
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-10
Recruiting
A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke
NCT07205328Acute Ischemic Stroke
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 2
360
Beijing
2025-10
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH)
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 2
156
Beijing
2025-09-30
Not yet open
A Study of CAR-T Cells in Subjects With Autoimmune Diseases
NCT07040917Autoimmune Diseases
Chinese PLA General Hospital
Phase EARLY_PHASE1
12
Beijing
2025-09-30
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
NCT07156500Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
204
Beijing
2025-09-30
Not yet open
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Severe Obesity
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Not yet open
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
NCT07200154Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-09-30
Recruiting
The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia
NCT07230197Fibromyalgia, Pregabalin, Dexmedetomidine
Beijing Tiantan Hospital
Not applicable
400
Beijing
2025-09-30
Recruiting
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms
NCT07479082Unruptured Intracranial Aneurysm, Headache, Vagus Nerve Stimulations
Beijing Tiantan Hospital
Not applicable
440
Beijing
2025-09-30
Recruiting
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
NCT07532434Ovarian Cancer, Breast Cancer
Peking University Third Hospital
Observational
480
Beijing
2025-09-30
Recruiting
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
NCT07196657Fibromyalgia, Pregabalin, Pain
Beijing Tiantan Hospital
Not applicable
1,116
Beijing
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
NCT07489534Multiple Myeloma
Daihong Liu
Phase 2
25
Beijing
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Not yet open
Advancing Assessment for Disorders of Consciousness
NCT07180589Disorders of Consciousness
Xuanwu Hospital, Beijing
Observational
200
Beijing
2025-09-25
Recruiting
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
NCT07584161Cervical Cancer, Endometrial Cancer
Xiaorong Hou
Not applicable
228
Beijing
2025-09-25
Not yet open
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
NCT07165418Renal Cell Carcinoma (RCC)
Peking University Cancer Hospital & Institute
Phase 3
116
Beijing
2025-09-25
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269Systemic Lupus Erythematosus (SLE)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
198
Beijing
2025-09-24
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism
NCT07190079Acute Pulmonary Embolism
Peking Union Medical College Hospital
Observational
343
Beijing
2025-09-24
Recruiting
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975Obesity/Overweight in Adult
Gan & Lee Pharmaceuticals.
Phase 3
420
Beijing
2025-09-23
Recruiting
A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)
NCT07683728Progressive Pulmonary Fibrosis
Zuojun Xu
Observational
600
Beijing
2025-09-23
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Not yet open
A Post-Market Study of Drug-Coated Peripheral Balloon Dilatation Catheter in Treating Femoropopliteal Artery Stenosis or Occlusive Lesions.
NCT07187128Femoropopliteal Artery Stenoses or Occlusive Lesions
BrosMed Medical Co., Ltd
Not applicable
150
Beijing, Chongqing
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chongqing, Dalian, Datong
2025-09-22
Recruiting
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
NCT07357623Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NCT07164170Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Not yet open
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
NCT07166380Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
Neurodawn Pharmaceutical Co., Ltd.
Phase 1/2
18
Beijing
2025-09-20
Recruiting
The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia
NCT07186751Fibromyalgia, Pregabalin, Venlafaxine, Pain
Beijing Tiantan Hospital
Not applicable
750
Beijin, Beijing
2025-09-20
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
NCT07178340Hepatoid Adenocarcinoma of Stomach
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-09-18
Recruiting
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
NCT06848842Colorectal Liver Metastases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-09-18
Recruiting
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07130604Plaque Psoriasis
InventisBio Co., Ltd
Phase 3
390
Beijing
2025-09-18
Not yet open
A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
NCT07190261Autoimmune Hemolytic Anemia
Bing Han
Phase 2
3
Beijing
2025-09-18
Recruiting
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
NCT07199270Health Adult Subjects
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
64
Beijing
2025-09-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Baotou, Beijing, Changde, Changsha, Chengdu, Chongqing, Dalian, Foshan
2025-09-17
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067Relapsed/Refractory Multiple Myeloma(MM)
Nanjing Legend Biotech Co.
Not applicable
35
Beijing, Tianjin, Wuhan
2025-09-16
Recruiting
A Clinical Study of GK02 in Malignant Ascites
NCT07378436Malignant Ascites Caused by Advanced Solid Tumors
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1
9
Beijing
2025-09-16
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Exploratory Clinical Study on the Safety of STR-P004
NCT07143617Autoimmune Diseases
Beijing GoBroad Hospital
Not applicable
39
Beijing
2025-09-16
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Fuzhou, Guangzhou, Beijing, Xi'an
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment
NCT07357272Hypertension (HTN), Sleep Apnea Syndrome, Obstructive
Beijing Anzhen Hospital
Observational
200
Beijing
2025-09-15
Recruiting
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07115485Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Henlius Biotech
Phase 2
60
Beijing
2025-09-15
Recruiting
The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia
NCT07171320Fibromyalgia, Pregabalin, Pain
Beijing Tiantan Hospital
Not applicable
384
Beijing
2025-09-15
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Not yet open
Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study
NCT07161167Obesity Rekated Cancer, Body Composition Changes, Survival, Mechanism
Peking Union Medical College Hospital
Observational
6,743
Beijing
2025-09-15
Recruiting
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
NCT07106892Colorectal Cancer (CRC)
Shanghai Henlius Biotech
Phase 2
60
Beijing, Jinan
2025-09-15
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
NCT07118319Amyotrophic Lateral Sclerosis (ALS)
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase 1
12
Beijing
2025-09-15
Not yet open
Acupuncture for Anxiety/Depression in Patients With Breast Cancer
NCT07183813Anxiety Depression, Breast Cancer, Acupuncture
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
360
Beijing
2025-09-15
Recruiting
TaVNS for Acute Intracerebral Hemorrhage
NCT06918964Intracerebral Hemorrhage
Beijing Tiantan Hospital
Not applicable
186
Beijing
2025-09-15
Recruiting
The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia
NCT07230171Fibromyalgia, Pregabalin, Esketamine
Beijing Tiantan Hospital
Not applicable
92
Beijing
2025-09-15
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
A Phase I Study of CREPT-618 in Locally Advanced HCC
NCT07364357Hepatocellular Carcinoma (HCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
13
Beijing
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Active, closed
ASKC200 for Knee Osteoarthritis Pain
NCT07742852Osteoarthritis (OA) of the Knee, Pain
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 2
175
Beijing
2025-09-12
Recruiting
Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations
NCT07127185Ceftobiprole
Chinese PLA General Hospital
Observational
150
Beijing
2025-09-12
Recruiting
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets
NCT07124221Hyperprolactinemia
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
382
Beijing
2025-09-12
Active, closed
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
NCT07147361Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
800
Beijing
2025-09-12
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
By invitation
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
NCT07520214Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Beijing Neurosurgical Institute
Phase EARLY_PHASE1
9
Beijing
2025-09-10
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
NCT07408024Rheumatoid Arthritis (RA)
Toll Biotech Co. Ltd. (Beijing)
Phase 2
24
Bengbu, Beijing, Puyang, Hohhot, Pingxiang, Linfen
2025-09-10
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
NCT07140809Hypertriglyceridemia
Shanghai JMT-Bio Inc.
Phase 1/2
48
Beijing
2025-09-09
Recruiting
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
NCT07305974IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Phase 2
30
Beijing
2025-09-08
Recruiting
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
NCT07079228Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3
602
Beijing
2025-09-08
Not yet open
CPET-based HIIT for MAFLD
NCT07177963Metabolic Dysfunction-Associated Fatty Liver Disease
Tang Yida
Not applicable
54
Beijing
2025-09-08
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Recruiting
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382Plaque Psoriasis
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xi’an, Hangzhou
2025-09-08
Recruiting
Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD
NCT07173920Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation
Peking University Sixth Hospital
Not applicable
62
Beijing
2025-09-08
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia
NCT07157852Fibromyalgia, Pregabalin, Mirogabalin, Pain
Beijing Tiantan Hospital
Not applicable
674
Beijing
2025-09-05
By invitation
The Study of ENB With Ultra-thin Cryobiopsy in the Diagnosis of Peripheral Pulmonary Nodules
NCT07326072Diagnosis
Beijing Chao Yang Hospital
Not applicable
228
Beijing
2025-09-05
Recruiting
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
NCT07148791IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Chinese PLA General Hospital
Phase 2
9
Beijing
2025-09-05
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Rows per page Showing 1601–1700 of 5484
Previous 15 16 17 18 19 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=17

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.